<?xml version="1.0"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
<channel>
<title>BloggingStocks</title>
<link>http://www.bloggingstocks.com</link>
<description>BloggingStocks</description>
<image>
<url>http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif</url>
<title>BloggingStocks</title>
<link>http://www.bloggingstocks.com</link>
</image>
<language>en-us</language>
<copyright>Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only.</copyright>
<generator>Blogsmith http://www.blogsmith.com/</generator><item><title><![CDATA[Merck shares plummet 10%: earnings topped estimates, but no guidance]]></title><link>http://www.bloggingstocks.com/2008/07/21/merck-shares-plummet-10-earnings-topped-estimates-but-no-gu/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2008/07/21/merck-shares-plummet-10-earnings-topped-estimates-but-no-gu/</guid><comments>http://www.bloggingstocks.com/2008/07/21/merck-shares-plummet-10-earnings-topped-estimates-but-no-gu/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/earnings-reports/" rel="tag">Earnings Reports</a>, <a href="http://www.bloggingstocks.com/category/mrk/" rel="tag">Merck and Co (MRK)</a></p><a href="http://finance.aol.com/quotes/merck-and-co-inc/mrk/nys">Merck &amp; Co., Inc.</a> (NYSE: <a href="http://finance.aol.com/quotes/merck-and-co-inc/mrk/nys">MRK</a>) <a href="http://money.aol.com/news/articles/qp/pr/_a/merck-reports-second-quarter-2008/rfid123630257">reported earnings</a> per share of 82 cents, but excluding restructuring charges, the pharmaceutical company said it earned 86 cents per share, topping <a href="http://www.bloggingstocks.com/2008/07/18/merck-earnings-preview-no-miracles-expected/">analyst estimates</a> of 83 cents per share. Revenue came in at $6.1 billion for the quarter, a decrease of 1% from the second quarter of 2007, but in line with estimates. Yet the stock is plummeting 10% in after-hours trading, after closing at $35.33, down 6.24% during the session.<br /><br />This shouldn't really be surprising, Merck is not providing 2008 equity income guidance and any long-term financial performance guidance while it is assessing the effects on the Vytorin/Zetia drugs after the <a href="http://www.bloomberg.com/apps/news?pid=20601087&amp;sid=aoWzJGwTRTSw&amp;refer=home">failed study</a> result. It also lowered sales guidance for Gardasil, which may not be surprising. But what is surprising is that the drugmaker also lowered sales estimates for its allergy-fighting Singulair.<br /><br />If investors thought Merck has its work cut out for it, this earnings report underscored the issue even more. Already punished 35% year-to-date, Merck shares will likely continue to be soft until a clear outlook can be seen. Right now, with so many open question and even the company not willing to make educated predictions, many will likely stay away.<p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2008/07/21/merck-shares-plummet-10-earnings-topped-estimates-but-no-gu/">Merck shares plummet 10%: earnings topped estimates, but no guidance</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Mon, 21 Jul 2008 18:05:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2008/07/21/merck-shares-plummet-10-earnings-topped-estimates-but-no-gu/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/1262807/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2008/07/21/merck-shares-plummet-10-earnings-topped-estimates-but-no-gu/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>earnings</category><category>gardasil</category><category>inthenews</category><category>merck</category><category>mrk</category><category>singulair</category><category>vytorin</category><category>zetia</category><dc:creator><![CDATA[Melly Alazraki]]></dc:creator><pubDate>Mon, 21 Jul 2008 18:05:00 EST</pubDate></item></channel></rss>
